www.praktickelekarenstvi.cz e10 PRAKTICKÉ LÉKÁRENSTVÍ AKTUÁLNÍ FARMAKOTERAPIE Farmakoterapie během kardiopulmonální resuscitace -hospital cardiac arrest. Am J Cardiol 2006; 358(9276): 105–109. 22. Goldsmith SR. Baroreceptor-mediated suppression of osmotically stimulated vasopressin in normal humans. J Appl Physiol 1988; 65: 1226–1230. 23. Prengel AW, Lindner KH, Keller A. Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Stroke 1996; 27: 1241–1248. 24. Fox AW, May RE, Mitch WE. Comparison of peptide and nonpeptide receptormediated responses in rat tail artery. J Cardiovasc Pharmacol 1992; 20: 282–289. 25. Currigan DA, Hughes RJ, Wright CE, Angus JA, Soeding PF. Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries: an in vitro study. Anesthesiology 2014; 121: 930–936. 26. den Ouden DT, Meinders AE. Vasopressin: physiology and clinical use in patients with vasodilatory shock: a review. Neth J Med 2005; 63: 4–13. 27. Mulligan KA, McKnite SH, Lindner KH, Lindstrom PJ, Detloff B, Lurie KG. Synergistic effects of vasopressin plus epinephrine during cardiopulmonary resuscitation. Resuscitation 1997; 35: 265–271. 28. Ullian ME. The role of corticosteriods in the regulation of vascular tone. Cardiovasc Res 1999; 41: 55–64. 29. Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology 1992; 77: 662–668. 30. Wenzel V. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004; 350(2): 105–113. 31. Turner DW. Vasopressin associated with an increase in return of spontaneous circulation in acidotic cardiopulmonary arrest patients. Ann Pharmacother; 2014; 48(8): 986–991. 32. Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 2000; 84: 339–346. 33. Myerburg RJ, Castellanos A. Therapy for cardiac arrhythmias. In Bonow RO, ed. Braunwalds Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia: Elsevier Saunders; 2012: 710. 34. Van Herendael H, Dorian P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Vasc Health Risk Manag 2010; 6: 465–472. 35. Huang J. The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. J Am Coll Cardiol; 2002; 40(2): 375–38336. Kudenchuk PJ. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999; 341(12): 871–787. 37. Dorian P. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med; 2002; 346(12): 884–890. 38. Pollak PT, Wee V, Al-Hazmi A, Martin J, Zarnke KB. The use of amiodarone for in-hospital cardiac arrest at two tertiary care centres. Can J Cardiol 2006; 22: 199–202. 39. Rea RS, Kane-Gill SL, Rudis MI, Seybert AL, Oyen LJ, Ou NN, Stauss JL, Kirisci L, Idrees U, Henderson SO. Comparing intravenous amiodarone or lidocaine, or both, outcomes for inpatients with pulseless ventricular arrhythmias. Crit Care Med 2006; 34: 1617–1623. 40. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134: 550. 41. Zhang Q, Li C. Combination of epinephrine with esmolol attenuates postresuscitation myocardial dysfunction in a porcine model of cardiac arrest. PLoS ONE 2013; 8: e82677. 42. Driver BE, Debaty G, Plummer DW, Smith SW. Use of esmolol after failure of standard cardiopulmonary resuscitation to treat patients with refractory ventricular fibrillation. Resuscitation 2014; 85: 1337–1341. 43. Varvarousi G, Stefaniotou A, Varvaroussis D, Xanthos T. Glucocorticoids as an emerging pharmacologic agent for cardiopulmonary resuscitation. Cardiovasc Drugs Ther 2014; 28: 477–488. 44. Smithline H, Rivers E, Appleton T, Nowak R. Corticosteroid supplementation during cardiac arrest in rats. Resuscitation 1993; 25: 257–264. 45. Tavakoli N, Bidari A, Shams Vahdati S. Serum cortisol levels as a predictor of neurologic survival in successfully resuscitated victims of cardiopulmonary arrest. J Cardiovasc Thorac Res 2012; 4: 107–111. 46. Tsai MS, Huang CH, Chang WT. The effect of hydrocortisone on the outcome of out- -of-hospital cardiac arrest patients: a pilot study. Am J Emerg Med 2007; 25: 318–325. 47. Mentzelopoulos SD, Malachias S, Chamos C. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA 2013; 310: 270–279. 48. Brown CG, Griffith RF, Neely D, Hobson J, Miller B. The effect of intravenous magnesium administration on aortic, right atrial and coronary perfusion pressures during CPR in swine. Resuscitation 1993; 26: 3–12. 49. Keller PK, Aronson RS. The role of magnesium in cardiac arrhythmias. Prog Cardiovasc Dis 1990; 32: 433–448. 50. Chen F, Lin Q, Chen G. Does intravenous magnesium benefit patients of cardiac arrest? A meta-analysis. Hong Kong J Emerg Med 2012; 19: 103–109. 51. Morton HJ, Thomas ET. Effect of atropine on the heart-rate. Lancet 1958; 2: 1313–131. 52. DeBehnke DJ, Swart GL, Spreng D, Aufderheide TP. Standard and higher doses of atropine in a canine model of pulseless electrical activity. Acad Emerg Med 1995; 2: 1034–1041. 53. Nagao K, Yagi T, Sakamoto T, et al. Atropine sulfate for patients with out-of-hospital car-
RkJQdWJsaXNoZXIy NDA4Mjc=